Prelude Therapeutics To Engage In Hematology And Oncology Summit
Prelude Therapeutics to join Citizens JMP Securities Hematology & Oncology Summit on Dec 2, featuring a fireside chat with its leadership.
Prelude Therapeutics Incorporated is a clinical-stage company specialising in precision oncology. It announced its participation in the upcoming Citizens JMP Securities Hematology and Oncology Summit today. The virtual event is scheduled for December 2, 2024.
On Monday, December 2, at 11:30 a.m. ET, Prelude’s Chief Executive Officer, Kris Vaddi, Ph.D., and President and Chief Medical Officer, Jane Huang, M.D., will participate in a fireside chat.
The live webcast of the discussion will be accessible through the Events and Presentations section of the company’s website. For convenience, a session recording will be archived and available for viewing on the site for 90 days.
Simantini Singh Deo works on the latest and trending news happening daily in the pharma world.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion